Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06939400

Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Glioblastoma Multiforme (GBM) Astrocytoma Glioblastoma Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.

Exclusion criteria

  • Photosensitizer allergy.
  • Severe coagulation disorder.
  • Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.
  • Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.

Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.

Treatment and study plan

Photodynamic Therapy (PDT)

Procedure

GBM patients recevied surgical combination photodynamic therapy

Other names: Surgical combination photodynamic therapy

GBM patients recevied traditional treatment options

Procedure

GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)

Primary outcomes

  1. Number of Participants with Treatment of Surgical combination Photodyanmic therapy

    Time frame: From June 2025 to June 2027

Study contacts

Contact information is provided by the study sponsor or research team.

Shaoshan Hu, Doctor

CONTACT

[email protected]

0571-85893451 ext. 0571-85893451

Yi Yuan, Doctor

CONTACT

[email protected]

0571-85893451

Sponsors and collaborators

Lead sponsor

Zhejiang Provincial People's Hospital

Other

Collaborators

  • The Second Affiliated Hospital of Harbin Medical University

Registry information

Official study title

Study on Precision Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 22, 2025
Registry last updated
Apr 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.